Clinical Trials

Other hematologic neoplasmPlasma cell

1,892 enrolled

Leukemia, Multiple Myeloma

NCT03477539 2026-03-09

Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma

49 enrolled 15 charts

Multiple Myeloma

NCT01758042 2026-03-06

BMT

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

10 enrolled

Immunoglobulin Light-chain Amyloidosis, Anemia, Aplastic, Anemia, Sickle Cell, Autoimmune Diseases, Hodgkin Disease, Leukemia, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Thalassemia, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Anemia, Diamond-Blackfan, Renal Insufficiency, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT03361306 2026-03-06

LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma

15 enrolled 26 charts

Multiple Myeloma, Recurrence

NCT03601078 2026-03-04

KarMMa-2

312 enrolled

Multiple Myeloma, Recurrence

NCT04328662 2026-03-04

A Study of Ninlaro in Real World Clinical Practice in China

482 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01919086 2026-03-02

Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma

30 enrolled 13 charts

Multiple Myeloma

NCT06549634 2026-02-27

Biomarkers of AKI in Patients Receiving Daratumumab

20 enrolled

GenitourinaryPlasma cell

Multiple Myeloma, Acute Kidney Injury

NCT00339963 2026-02-20

Genome Expression in Lymphoma, Leukemia and Multiple Myeloma

1,340 enrolled

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Plasma Cell

NCT02833610 2026-02-18

A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency

55 enrolled

Multiple Myeloma

NCT05804032 2026-02-18

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

514 enrolled

Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Paraproteinemias

NCT05561751 2026-02-12

Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

30 enrolled

Multiple Myeloma

NCT04322292 2026-02-11

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

9 enrolled

Multiple Myeloma

NCT05014412 2026-02-10

MagnetisMM-9

86 enrolled 16 charts

Multiple Myeloma, Recurrence

NCT03275285 2026-02-09

IKEMA

302 enrolled 38 charts 1 FDA

Multiple Myeloma

NCT04674813 2026-02-09

A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

130 enrolled

Multiple Myeloma

NCT01237054 2026-02-06

Imaging in MGUS, SMM and MM

31 enrolled 13 charts

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma

NCT01745640 2026-02-05

IFM2010-02

63 enrolled

Chromosome 17 deletion, Multiple Myeloma

NCT03275103 2026-02-05

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

355 enrolled

Multiple Myeloma

NCT05918185 2026-02-03

Evaluation of Comprehensive Geriatric Assessment and Laboratory Biomarkers in Elderly Patients With Multiple Myeloma

56 enrolled

Multiple Myeloma

NCT03839459 2026-01-28

Denosumab for Smoldering Multiple Myeloma

20 enrolled 8 charts

Smoldering Multiple Myeloma

NCT03159702 2026-01-27

Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation

Other hematologic neoplasmPlasma cell

43 enrolled 9 charts

Hematologic Diseases, Multiple Myeloma, Hematologic Neoplasms

NCT02389517 2026-01-22

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

42 enrolled 11 charts

Multiple Myeloma, Neoplasm, Residual

NCT07354191 2026-01-21

Outcome of Multiple Myeloma Associated With Autoimmune Hemolytic Anemia

66 enrolled

Multiple Myeloma

NCT02969837 2026-01-16

Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma

46 enrolled 10 charts

Multiple Myeloma

NCT05063591 2026-01-15

BRUOG-407

LymphoidMyeloidOther hematologic neoplasmPlasma cell

18 enrolled 8 charts

Leukemia, Lymphoma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT02441686 2026-01-13

Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma

46 enrolled 13 charts

Multiple Myeloma

NCT02619682 2026-01-08

Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma

30 enrolled 11 charts

Multiple Myeloma

NCT05625971 2026-01-07

NIRVANA

36 enrolled

Neoplasm, Residual, Neoplasms, Plasma Cell

NCT01208766 2026-01-06

HO95

1,503 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05228470 2026-01-06

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

39 enrolled 15 charts

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT04364256 2026-01-02

Muscle Stimulation for Physical Function During Stem Cell Transplant

46 enrolled

Lymphoma, Multiple Myeloma, Muscular Atrophy, Hematologic Neoplasms

NCT05355987 2026-01-02

SOSAM

20 enrolled

Other hematologic neoplasmPlasma cell

Multiple Myeloma

NCT04952766 2025-12-23

EREVA

Phase 4 Completed

196 enrolled

Acquired Immunodeficiency Syndrome, Diabetes Mellitus, Type 2, Hypergammaglobulinemia, Multiple Sclerosis, Neoplasms, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT01665794 2025-12-22

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

25 enrolled

Multiple Myeloma

NCT00466674 2025-12-19

IFM 2005-03

13 enrolled

Neoplasms, Plasma Cell

NCT03180736 2025-12-19

EMN14

304 enrolled 19 charts 1 FDA

Phase EARLY_PHASE1 Completed

Multiple Myeloma

NCT03631043 2025-12-19

Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma

30 enrolled

Smoldering Multiple Myeloma

NCT03317899 2025-12-17

Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

77 enrolled 17 charts

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT05700747 2025-12-16

Health Through Activity: A Pilot Study of a Rehabilitation Intervention for People Living With Multiple Myeloma

5 enrolled 10 charts

Multiple Myeloma

NCT05182073 2025-12-12

FT576 in Subjects With Multiple Myeloma

31 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02362035 2025-12-11

KEYNOTE145

Phase 1/2 Completed

161 enrolled 29 charts

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT02302495 2025-12-08

IFM2012-03

32 enrolled

Multiple Myeloma

NCT05065866 2025-12-04

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

14 enrolled

Hodgkin Disease, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Neoplasms, Plasma Cell

NCT06322927 2025-12-04

iPREFER

9 enrolled

Multiple Myeloma

NCT04830046 2025-11-26

Covid-19 Vaccine Responsiveness in MM and Waldenstrom

146 enrolled

COVID-19, Immune System Diseases, Waldenstrom Macroglobulinemia, Multiple Myeloma

NCT02244125 2025-11-24

PCD

100 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT04783038 2025-11-21

Determining The Impact Of Distance Reiki On Patient Reported QOL And Immunity Among Multiple Myeloma Patients

30 enrolled